The mediator of information: coherence, cohesion and continuity in transmission of the information
Vander Haegen, Marie ; ; et al
Poster (2013, March 15)Detailed reference viewed: 28 (8 ULg)
Medical aspects of obesity.
Scheen, André ; Luyckx, Françoise
in Acta Chirurgica Belgica (1999), 99(3), 135-9
Obesity poses a serious health hazard and its treatment is often disappointing. Major advances have been made during recent years in the understanding of body weight regulation, with the discovery of ... [more ▼]
Obesity poses a serious health hazard and its treatment is often disappointing. Major advances have been made during recent years in the understanding of body weight regulation, with the discovery of leptin, a protein produced by adipocytes and acting on the central nervous system to reduce food intake, and that of beta-3 adrenergic receptors and uncoupling proteins which contribute to stimulate energy expenditure. Numerous metabolic complications are associated with abdominal obesity and most of them, such as diabetes mellitus, dyslipidaemias and arterial hypertension, appear to be linked to insulin resistance and may be part of the socalled metabolic syndrome or syndrome X. While very-low-calorie diets are usually effective in the short-term, they cannot, in the long-term and for most patients, solve the problem of severe obesity. Pharmacological antiobesity treatment may include drugs that reduce food intake, drugs that increase energy expenditure and drugs that affect nutrient partitioning or metabolism. All of these pharmacological approaches have potential efficacy, but unfortunately serious limitations. This is also the case of mechanical means, such as intragastric balloons. Consequently, bariatric surgery may be considered as a valuable alternative therapy in well-selected patients with morbid obesity refractory to classical treatments. In conclusion, obesity is a chronic disease and should be treated as such with reasonable expectations. [less ▲]Detailed reference viewed: 25 (1 ULg)
Medical communication at shift change and human error: Could a cognitive support make health care safer?
Gillet, Aline ; Ghuysen, Alexandre ; D'Orio, Vincenzo et al
Conference (2013, May 24)Detailed reference viewed: 82 (8 ULg)
Medical education and training in geriatrics in the 21st centrury. Where do we come from - where do we go ?
; PETERMANS, Jean
in European Geriatric Medicine (2015), in pressDetailed reference viewed: 30 (0 ULg)
Medical imaging and MRI in nail disorders: report of 119 cases and review of the literature
Richert, Bertrand ;
in Dermatologic Therapy (2002), 15
Radiographs remain the golden standard for exploration of the bony structures located beneath the nail plate, but they provide no information on the perionychium. Until a few years ago the nail apparatus ... [more ▼]
Radiographs remain the golden standard for exploration of the bony structures located beneath the nail plate, but they provide no information on the perionychium. Until a few years ago the nail apparatus was deprived of investigative medical imaging. Glomus tumor was the only condition that was explored using invasive techniques such as angiography or scintigraphy. High-frequency ultrasound rapidly came up against technical limits. High-resolution magnetic resonance imaging (MRI) offers a superior alternative in detection of distal lesions as well as their relationship with the adjacent structures. MRI provides an accurate analysis of the nail apparatus with detection of lesions as small as 1 mm. This noninvasive technique will allow us to better understand, diagnose, and treat pathologies of the distal phalanx. [less ▲]Detailed reference viewed: 16 (0 ULg)
The medical management of severe acute and chronic ulcerative colitis--current recommendations from the Belgian Working Group.
; ; Devos, Martine et al
in Acta Gastro-Enterologica Belgica (2000), 63(3), 273-4Detailed reference viewed: 10 (0 ULg)
Medical management of urinary incontinence and retention disorders
in Twedt, David; Bonagura, John (Eds.) Kirk's Current Veterinary Therapy; Small Animal Practice, XV (2014)Detailed reference viewed: 81 (15 ULg)
Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive?
; ; et al
in Indian Heart Journal (2009), 61(1), 14-23
Rheumatic Heart Disease (RHD) is well known to be an active inflammatory process which develops progressive calcification and leaflet thickening over time. The potential for statin therapy in slowing the ... [more ▼]
Rheumatic Heart Disease (RHD) is well known to be an active inflammatory process which develops progressive calcification and leaflet thickening over time. The potential for statin therapy in slowing the progression of valvular heart disease is still controversial. Retrospective studies have shown that medical therapy is beneficial for patients with calcific aortic stenosis and recently for rheumatic valve disease. However, the prospective randomized clinical trials have been negative to date. This article discusses the epidemiologic risk factors, basic science, retrospective and prospective studies in valvular heart disease and a future clinical trial to target RHD with statin therapy to slow the progression of this disease. Recent epidemiological studies have revealed the risk factors associated with valvular disease include male gender, smoking, hypertension and elevated serum cholesterol and are similar to the risk factors for vascular atherosclerosis. An increasing number of models of experimental hypercholesterolemia demonstrate features of atherosclerosis in the aortic valve (AV), which are similar to the early stages of vascular atherosclerotic lesions. Calcification, the end stage process of the disease, must be understood as a prognostic indicator in the modification of this cellular process before it is too late. This is important in calcific aortic stenosis as well as in rheumatic valve disease. There are a growing number of studies that describe similar pathophysiologic molecular markers in the development of rheumatic valve disease as in calcific aortic stenosis. In summary, these findings suggest that medical therapies may have a potential role in patients in the early stages of this disease process to slow the progression of RHD affecting the valves. This review will summarize the potential for statin therapy for this patient population. [less ▲]Detailed reference viewed: 10 (2 ULg)
Medical Treatment in Cushing’s Syndrome : Dopamine Agonists and Cabergoline
Petrossians, Patrick ; Thonnard, Anne-Sophie ; Beckers, Albert
in Neuroendocrinology (2010), 92((supp. 1)), 116-19
Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also ... [more ▼]
Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also appear in a number of secretory tumors in various locations, DA agonists have elicited some interest as a medical treatment for hypercorticism. Non-iatrogenic Cushing’s syndromes are due in 70% of the cases to a pituitary adrenocorticotropic hormone (ACTH) producing adenoma, and, less frequently, to an adrenal adenoma or an ectopic ACTH secretion by a neuroendocrine tumor. First-line treatment in Cushing’s syndrome consists of the surgical removal of the secreting tumor. However, surgery may not achieve a complete cure in a number of cases, hence emphasizing the potential benefit of a medical complementary treatment, which could also benefit patients as an alternative approach, either when waiting for, or when the patient is not eligible for surgery. Studies of corticotropic adenomas have shown that 80% of these tumors express D2 receptors. Clinical trials of DA agonists in Cushing’s disease have shown an inhibitory effect of these drugs with an inhibition of ACTH secretion and/or a decrease of tumor size. There are only a few cases of documented use of DA agonists in ectopic ACTH secretion, but when the tumor expresses DA receptors, DA agonists may represent a useful complementary treatment. DA receptors are also expressed in normal and tumoral adrenals, suggesting a potential use of DA agonists in Cushing’s syndrome secondary to adrenal tumors. However, clinical data regarding this specific situation are very scarce, maybe due to the relatively high rate of surgical cure of adrenal adenomas. In conclusion, DA agonists represent a potential preparatory or complementary treatment for endogenous Cushing’s syndrome, especially in Cushing’s disease. These compounds may be underused as suggested by the scarce number of publication and case reports in the literature. In the future, association of these drugs with somatostatin analogs may also prove beneficial. [less ▲]Detailed reference viewed: 43 (6 ULg)
Medical treatment of chronic anal fissure. Where do we stand on reversible chemical sphincterotomy?
Van Kemseke, Catherine ; Belaiche, Jacques
in Acta Gastro-Enterologica Belgica (2004), 67(3, Jul-Sep), 265-271
Anal fissure is a common problem which can evolve to chronicity. Chronic anal fissure is thought to be an ischemic ulceration related to sphincter hypertonia. Lateral internal sphineterotomy, the most ... [more ▼]
Anal fissure is a common problem which can evolve to chronicity. Chronic anal fissure is thought to be an ischemic ulceration related to sphincter hypertonia. Lateral internal sphineterotomy, the most common treatment for chronic anal fissure, may cause permanent injury to anal sphincter leading to fecal incontinence. To avoid such side effect were developed medications producing a temporary or reversible sphincterotomy reducing the sphincter pressure only until the fissure has healed : nitrates, calcium channel antagonists and botulinum toxin. Authors aimed to summary the state of research on such treatments (efficacy, side effects, recurrence risk) and to clarify the role of these different medical options in the current treatment of chronic anal fissure. [less ▲]Detailed reference viewed: 182 (0 ULg)
Le medicament du moi. Dabigatran etexilate (Pradaxa): anticoagulant oral, inhibiteur direct selectif de la thrombine
Lancellotti, Patrizio ; Scheen, André
in Revue Médicale de Liège (2010), 65(10), 588-92
Dabigatran (Pradaxa) is a new oral, direct, selective and reversible thrombin inhibitor (factor IIa) acting as anticoagulant. Pradaxa does not require monitoring or dose adjustment, except in cases of ... [more ▼]
Dabigatran (Pradaxa) is a new oral, direct, selective and reversible thrombin inhibitor (factor IIa) acting as anticoagulant. Pradaxa does not require monitoring or dose adjustment, except in cases of moderate renal insufficiency or in elderly patients (>75 years old). It is currently indicated for prophylaxis against venous thromboembolism after total hip or knee replacement surgery. Pradaxa has been shown to be as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip or knee replacement surgery, with a similar safety profile. The recommended dose of 220 mg is administered once-daily, starting with a half-dose 1-4 h after surgery. The total duration of treatment is 10 days for knee surgery and 28-35 days in case of hip replacement. Contrary to enoxaparin, with Pradaxa there is no risk of drug-related thrombocytopenia. Of note, this promising new anticoagulant has also shown to be more effective than warfarin for stroke prevention in patients with non-valvular atrial fibrillation and as effective as warfarin for the treatment of acute venous thromboembolism (indications not recognized yet). [less ▲]Detailed reference viewed: 251 (4 ULg)
Le médicament du mois - Le Valaciclovir (Zelitrex)
Pierard, Gérald ; Nikkels, Arjen
in Revue Médicale de Liège (1997), 52(8), 553-555
Un progrès important vient d'être réalisé dans le traitement du zona. Le valaciclovir (Zelitrex) est un nouveau médicament oral qui est en fait un précurseur de l'aciclovir. Sa biodisponibilité supérieure ... [more ▼]
Un progrès important vient d'être réalisé dans le traitement du zona. Le valaciclovir (Zelitrex) est un nouveau médicament oral qui est en fait un précurseur de l'aciclovir. Sa biodisponibilité supérieure à celle de l'aciclovir est à l'origine d'un progrès thérapeutique majeur dans la prise en charge du zona cutané chez des sujets immunocompétents de plus de 50 ans et du zona ophtalmique quel que soit l'âge du sujet. Le valaciclovir réduit tant la prévalence que la sévérité des douleurs associées au zona. [less ▲]Detailed reference viewed: 151 (0 ULg)